Cempra grant could yield up to $58 million
CHAPEL HILL -- Cempra, Inc., a clinical-stage company that’s working to develop antibiotics, on Tuesday announced a five-year contract worth up to $58 million for development of a pneumonia treatment.
The Biomedical Advanced Research and Development Authority, which is part of the U.S. Department of Health and Human Services, awarded the contract for the development of solithromycin to treat infections in children and for the treatment of infections by bioterror threat pathogens, according to a news release.
Solithromycin is Cempra's lead product candidate. It’s currently in Phase 3 development for treatment of community-acquired bacterial pneumonia in adults.
The contract is for a two-year base period with guaranteed funding of $17.7 million. It can be extended up to five years for a total of $58 million.
Monsanto site in RTP recognized
DURHAM – The Research Triangle Park site for the seed and agriculture products company Monsanto Co. was recognized Friday by the N.C. Department of Labor’s Occupational Safety and Health Division for its safety and health management program.
The site received the “Rising Star” award, according to a news release, that required an audit demonstrating the quality of the company’s safety program. Friday’s speakers included N.C. Commissioner of Labor Cherie Berry and Monsanto executives.
The company has more than 500 facilities in more than 60 countries, including 275 research and development sites. Monsanto’s RTP location, where the company has biotechnology research operations, employs 60.